Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Public ClinicalTrials.gov record NCT04784715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.
Study identification
- NCT ID
- NCT04784715
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,157 participants
Conditions and interventions
Conditions
Interventions
- Trastuzumab deruxtecan Drug
- Placebo Drug
- Taxane Drug
- Pertuzumab Drug
- Trastuzumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 26, 2021 (Actual)
- Primary completion
- May 3, 2027 (Estimated)
- Completion
- Dec 31, 2029 (Estimated)
- Last update posted
- Oct 22, 2026
2021 – 2029
United States locations
- U.S. sites
- 30
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85711 | — |
| Research Site | Springdale | Arkansas | 72762 | — |
| Research Site | Glendale | California | 91204 | — |
| Research Site | Glendale | California | 91206 | — |
| Research Site | Longmont | Colorado | 80501 | — |
| Research Site | Miami | Florida | 33176 | — |
| Research Site | Palm Bay | Florida | 32909 | — |
| Research Site | Plantation | Florida | 33324 | — |
| Research Site | Atlanta | Georgia | 30318 | — |
| Research Site | Louisville | Kentucky | 40241 | — |
| Research Site | Silver Spring | Maryland | 20904 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Jackson | Mississippi | 39213 | — |
| Research Site | Las Vegas | Nevada | 89128 | — |
| Research Site | Summit | New Jersey | 07901 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Shirley | New York | 11967 | — |
| Research Site | York | Pennsylvania | 17403 | — |
| Research Site | Germantown | Tennessee | 38138 | — |
| Research Site | Dallas | Texas | 75203 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Denton | Texas | 76201 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | San Antonio | Texas | 78240 | — |
| Research Site | Shenandoah | Texas | 77380 | — |
| Research Site | Tyler | Texas | 75702 | — |
| Research Site | Norfolk | Virginia | 23502 | — |
| Research Site | Roanoke | Virginia | 24014 | — |
| Research Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 253 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04784715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2026 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04784715 live on ClinicalTrials.gov.